Hematopoietic cell transplant (HCT) recipients have a substantial risk of developing secondary solid cancers (SSCs). The aim of this retrospective study was to compare the incidence of SSC in a monocentric cohort of thalassemia major (TM) patients (n = 122) who received HCT versus an hematopoietic cell donor monocentric cohort (n = 122) and versus a large multicenter cohort of age-and sex-matched TM patients (n = 244) who received conventional therapy. With a median follow-up of 24 years, 8 transplanted patients were diagnosed with SSC at a median of 18 years after HCT and at a median age of 33 years. Three patients died of cancer progression and 5 are living after a follow-up ranging from 10 months to 16 years after SSC diagnosis. The 30-year cumulative incidence of developing SSC was 13.24%. The occurrence of solid cancers in the hematopoietic cell donor cohort was limited to only one case for a significantly lower cumulative incidence (3.23%, P = 0.02) and to 3 cases in the cohort of nontransplant patients for a significantly lower cumulative incidence (1.32%, P = 0.005). This study shows that the magnitude of increased risk of SST is fourfold to sixfold for patients treated with HCT as compared with hematopoietic cell donors and nontransplant patients.
INTRODUCTION
Thalassemia major (TM) is a genetic disorder resulting in absent or reduced β-globin chain synthesis and severe hemolytic anemia. In the past 4 decades, the optimization of RBC transfusion programs, the introduction of the oral iron chelators and a tailored iron chelation therapy T2* magnetic resonance imaging have resulted in a remarkable improvement in the survival and life expectancy of affected patients. [1] [2] [3] So far, TM has been transformed from a lethal disease into a chronic disease of the adulthood. As a consequence of improved survival, aging patients are more likely to develop malignancies of various organs. An Italian retrospective study demonstrated that cancer was the fifth cause of death after heart disease, infection, cirrhosis and thrombosis, with a prevalence of 3.6% in 1073 patients. 4 From several studies published in literature and recently reviewed by Zanella et al. 5 in 2016, patients with TM appear to be more exposed than the general population to the risk of cancer, in particular at a younger age. Iron overload, transfusion-transmitted viruses and immunosuppression secondary to RBC transfusions can all contribute to increase the risk.
Allogeneic hematopoietic cell transplantation (HCT) is the only definitive cure currently available for patients with TM who have a related or unrelated HLA identical donor. 6, 7 In the past two decades, transplantation techniques have improved and transplant-related mortality has fallen to 10% or even lower, especially in young low-risk children who received HCT from HLA identical sibling donor. The probability of overall event-free survival has been reported to be as high as 89-97% for low-risk patients and 80-87% for high-risk patients. 8 Secondary solid cancers (SSCs) have been described after syngeneic, allogeneic and autologous HCT, in particular for patients affected by hematologic malignancies. The magnitude of the increased risk of SSC has ranged from 2.1-fold to 2.7-fold when compared with an age-and sex-matched general population. 9 For patients surviving for 410 years after transplantation, the risk of SSC was reported to be 8.3 times as high as expected in the general population. There is limited information about the incidence of SSC in patients who received an allogeneic HCT for TM. The aim of this study was to determine the incidence of SSC in 122 patients with TM who received HCT in a single center and survived for 43 years after transplantation and to compare it with that observed in 122 donors of hematopoietic stem cells and in 244 patients with TM who were treated with RBC transfusions and iron chelation therapy.
MATERIALS AND METHODS

Study design and data collection
This is a retrospective analysis in which the risk of SSC was studied in a cohort of 122 patients affected by TM who survived for at least 3 years after an allogeneic HCT performed at the Bone Marrow Transplant Center of Pescara, Italy. The risk of SSC was compared with that of the 122 individuals who served as donors of hematopoietic stem cells for the transplant. Moreover, the risk of SSC was compared with that of 244 nontransplanted patients affected by TM who were randomly selected in the MIOT (Myocardial Iron Overload in Thalassemia) multicenter Italian registry.
Information on second cancer, including date of diagnosis, site of involvement, morphologic features, therapy and outcome, was collected by a review of medical records provided either by the patient or by the donor or by the physician who made the diagnosis and had taken care of the patient. Information on second cancer and vital status was completed on 10 October 2016.
The study was approved by the local institutional review board. Informed consent for the transplant was obtained from all patients and donors or their legal guardians in accordance with the Declaration of Helsinki.
Patients who received an allogeneic HCT Between May 1983 and July 2013, 134 consecutive patients (males 67) with TM were treated with HCT in Pescara. Details about the transplant protocol have been described elsewhere. 11 Each recipient of marrow transplantation was given unique patient number (UPN).
Eleven patients (8.2%) died of transplant-related complications between days 12 and 212 after transplant (median, day 42). One patient (UPN 291) died of accident 2 years after transplantation. A total of 122 patients survived for 43 years after transplant and were considered in this study. Their clinical and transplant characteristics are outlined in Table 1 . The patient's median age at the time of HCT was 10 years (range, 1 to 29). Liver biopsy was performed in 76 patients before transplant and was analyzed from 2 different pathologists. The histological grading and staging of chronic hepatitis was made following the classification of Ishak et al.
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In the first 5 years after transplantation, all patients were followed annually and every 2 to 3 years later or when a new clinical event appeared. They were constantly informed about the importance of an accurate screening for common cancers.
Donors of hematopoietic stem cells
This cohort included 122 individuals (67 males) who served as donors of hematopoietic stem cells. Donors were HLA genotypically identical siblings in 113 cases, HLA phenotypically identical family members in 6 cases (3 fathers, 2 mothers, 1 uncle) and matched unrelated in 3 cases. The donor's median age at the time of donation was 10 years (range, 1 to 48).
Hematopoietic stem cells were collected either from bone marrow in 120 cases or from peripheral blood following mobilization with G-CSF in one and from matched related cord blood in one.
Patients with TM treated with conventional therapy
This cohort included 244 patients (122 males) who were randomly selected from the multicenter MIOT Network on the basis of 2:1 matching by age and gender with the patients who received HCT. The MIOT network involves 70 Italian thalassemia centers and 9 Italian magnetic resonance imaging sites, linked by a web-based database, configured to collect and share patients' anamnestic, clinical and diagnostic data from the birth to the last magnetic resonance imaging scan. 10 The two nontransplanted patients more close in age, considering also the month of birth, were selected. To verify the quality of the data, each hematologist or pediatrician completed and returned by e-mail a case report form detailing the neoplastic history of his/her patients.
Patients were born on or after 8 January 1966 and were diagnosed as being affected by TM (transfusion-dependent) before the age of 3 years. They were uniformly treated with regular RBC transfusions and chelation therapy. Their demographic and clinical characteristics are outlined in Table 2 .
Statistical analysis
Descriptive statistics were used to characterize the study population. Continuous variables with normal distribution were described as mean ± s.d., whereas nonnormal variables were represented with median and 25th and 75th percentiles. Categorical variables were expressed as frequencies and percentages.
For each transplant recipient, the number of person-years at risk was calculated from the date of transplantation until the date of completion of the study, death or diagnosis of a SSC, whichever occurred first. For each donor and nontransplanted TM patient the same time at risk of the correspondent transplanted patient was used. In case of death or tumor, the time at risk was the difference between the date of death or tumor and the date of transplantation of the matched patient. Abbreviations: BU = busulfan; CSA = cyclosporine A; CY = cyclophosphamide; FLU = fludarabine; HBV = hepatitis B virus; HCT = hematopoietic cell transplantation; HCV = hepatitis C virus; HSC = hematopoietic stem cell; MTX = methotrexate; TH = thiotepa; TNC = total nucleated cell; TREO = treosulfan.
The cumulative incidence was used to assess the absolute risk of cancer over different periods of time. It was estimated using the Kaplan-Meier product-limit method without accounting for competing risk events. Differences between groups were tested using the log-rank test.
P-values of o0.05 were considered statistically significant. Analyses were performed using R Statistical Software (version 3.3.3; R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
At the
Seven patients were transfusion free and cured of their disease and one patient (UPN 23) showed graft rejection early at 6 months after HCT with gradual reappearance of thalassemia and necessity of RBC transfusions and iron chelation. Details of the eight patients who were diagnosed with SSC are shown in Table 3 . No hematological malignancy was detected. SSC was diagnosed at a median of 18 years (range, 3.2 to 29) after transplantation. The median age of 8 patients at the time of SSC diagnosis was 33 years (range, 13 to 41). Three patients died of cancer progression and 5 are alive and doing well after a follow-up ranging from 10 months to 16 years. Noteworthy, all three patients who were diagnosed with oropharingeal cancer were affected by mild to moderate chronic GvHD with particular extension to oral cavity. The cumulative incidence of SSC was 0.82% (95% confidence interval (CI), 0.12-5.68%) at 10 years from transplant, 3.86% (95% CI, 1.46-9.99) at 20 years from transplant and 13.24% (95% CI, 6.01-27.81) at 30 years from transplant ( Figure 1a) .
Among 122 hematopoietic stem cell donors, only one developed triple-negative breast cancer 28 years after donation at the age of 38 years. This donor had no family history of cancer or other tumor risk factors. Currently this patient is alive and receiving only palliative therapy after failure of several lines of chemotherapy. At 10 and 20 years after hematopoietic stem cell donation, the cumulative incidence of solid cancer was 0, whereas at 30 years it was 3.23% (95% CI, 0.46-20.77). Compared with the cumulative incidence of transplanted patient, the difference was statistically significant (P = 0.02; Figure 1b) .
Among 244 patients with TM treated with conventional therapy, 3 cases of solid cancers were discovered. One patient (male) was diagnosed with thyroid carcinoma at the age of 29 years. Following thyroidectomy, he received adjuvant therapy with radioactive iodine and is living and now doing well after 10 years. One patient (male) was diagnosed with bilateral pheocromocytoma at the age of 9 years for which he underwent double surgical intervention. He is now living and doing well at 10 years from diagnosis. The third patient (female) was diagnosed with Hodgkin's lymphoma at the age of 17 years. At 7 months from diagnosis, she is now receiving specific chemotherapy. In this cohort of patients, the cumulative incidence of solid cancer was 1.32% (95% CI, 0.43-4.04) after 10, 20 and 30 years. Compared Abbreviations: DFO = desferioxamine; DFP = deferiprone; DFX = deferasirox; HBV = hepatitis B virus; HCV = hepatitis C virus; TM = thalassemia major. Abbreviations: F = female; HCT = hematopoietic cell transplantation; HBV = hepatitis B virus antibody; HCV = hepatitis C virus antibody; M = male; NEG = negative; POS = positive; SSC = secondary solid cancer; UPN = unique patient number.
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DISCUSSION
TM is a complex disease that is one of the most common genetic disorders in the world, in particular in Mediterranean Regions and South and Southeast Asia, although immigration is changing the geography of this disease. Treatment for TM has dramatically improved in the past decades. 3, 13, 14 Patients should now live full lives with careers and children of their own. Unfortunately, some patients die prematurely and many others develop morbid preventable complications. 4 To date, transplantation offers the only complete clinically available cure for TM patients. However, it is well known that patients treated with allogeneic HCT using both myeloablative or reduced-intensity conditioning therapy are at an increased lifelong risk of developing SSC. 9, [15] [16] [17] [18] [19] [20] The reported cumulative incidence of SSC following allogeneic transplantation ranges from 1.2 to 1.6% at 5 years, from 2.2 to 6.1% at 10 years and from 3.8 to 14.9% at 15 years post HCT. Risk factors associated with the development of SSC include: use of TBI and/or high-dose chemotherapy for conditioning regimen, transplant from HLA nonidentical donors, prolonged immunodeficiency as consequence of conditioning therapy and immunosuppressive drugs used as prophylaxis and treatment of GvHD, infections (EBV, hepatitis C virus, hepatitis B virus). Chronic GvHD was an independent risk factor for all SSCs, especially for cancer of the oral cavity. Although SSC and hematologic malignancies have been well described in patients allotransplanted for severe aplastic anemia and other nonmalignant hematologic diseases, there is very limited information about the development of SSC in patients allotransplanted for TM. The occurrence of solid cancer have been described either in TM patients or in patients with thalassemia intermedia. 4, 21, 22 In addition, hematologic malignancies such as leukemia and lymphoma have been frequently diagnosed in TM patients. 22 What seems real from all these studies and by still others is that the frequency of malignant diseases in patients with TM or thalassemia intermedia is actually increased when compared with that of the normal population. Although the reasons for this higher frequency might be multifactorial, three risk factors deserve to be emphasized: iron overload, transfusiontransmitted infections and decreased immune surveillance secondary to RBC transfusions and high body iron stores. Since 1988, iron has been proved to be carcinogenic. 23 From both in vitro and in vivo studies, we know that iron overload has been associated with various mechanisms capable of inducing carcinogenic transformation. They can essentially be traced to a direct effect through the inactivation of tumor suppressor proteins and to an indirect effect through the formation of reactive oxygen species, iron-induced lipid peroxidation and immune deficit. 24 No systematic long-term data are available in literature about the incidence of SSC following HCT for TM patients in comparison with hematopoietic cell donors and TM patients well transfused and well chelated. Our study describes the occurrence of SSC in eight patients who received an allogeneic HCT in a single center. They were part of a group of 122 patients who survived after HCT and were longitudinally followed for a very long time (median follow-up 24 years). One patient was receiving regular RBC transfusions and iron chelation therapy following an early graft rejection that resulted in TM recurrence. The other seven patients were thalassemia free and cured of their disease. In two cases a very rare cancer was diagnosed, Merkel cell carcinoma (UPN 23) and carcinoma of parotid gland (UPN 32). Both cases were resistant to chemotherapy and resulted in death after a very complicated and rapid course. The surgery was the only treatment for two patients to remove colorectal cancer in one case (UPN 140) and the carcinoma of the uterine cervix in the other one (UPN 384). One thyroid carcinoma was diagnosed in a female patient Secondary cancer after HCT for thalassemia major S Santarone et al (UPN 136), who is now receiving radiometabolic therapy. Finally, three patients were diagnosed with cancer of the oral cavity. Noteworthy, all three patients were affected by mild (one case) to severe (two cases) chronic GvHD with mouth involvement and requiring moderate (UPN 257) or intensive immunosuppressive therapy for a long time. All three patients showed persistent lichenoid lesions of the oral cavity and xerostomia after discontinuation of immunosuppressive therapy as a result of the prior chronic GvHD manifestations. One patient (UPN 275) did not respond to chemotherapy and died after 2 years, whereas the other two patients received chemotherapy and are living after 8 years (UPN 257) and 1 year (UPN 290) of cancer diagnosis, respectively. From these data, as the early diagnosis of tumors of the oral cavity is critical for their complete eradication, close serial monitoring of the mouth is recommended to promote early detection and intervention. Consultation with specialists in dental/oral medicine is strongly indicated. Of relevance in our study, when comparing the cumulative incidence of SSC at 30 years of the allotransplanted cohort with that of hematopoietic cell donor and that of patients with TM receiving RBC transfusions and iron chelation since early childhood, we found significantly increased incidence in allotransplanted patient. In general, although our results in terms of SSC have been observed in a single cohort of patients (N = 122) and certainly deserve to be confirmed in larger registry studies on TM transplanted patients, a reflection must be made about the indication of HCT in patients with TM well treated, especially in light of the improvements of survival and life expectancy produced by the standard therapy. To date, in developed countries HCT for TM patients is not an obvious and obligated choice such as in patients with hematological malignancies. Therefore, the families of patients with TM should be thoroughly informed about the possibility of developing SSC over time.
In conclusion, systematic prospective monitoring and close clinical observation is mandatory for all TM survivors after allogeneic HCT. 25, 26 Primary care and transplant physicians must be aware of the risk of second malignancies after transplant. Most importantly, the development of cancer screening guidelines is strongly recommended, so that physicians can provide state-ofthe-art counsel and care for the benefit of all patients.
